Clinical Trials Browser

Active not recruiting × Nasopharyngeal Carcinoma × 1 year × Clear all

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

Clinical Trials

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

POINT

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Optimization of Cervical Nodal CTV for Early and Medium Stage NPC

Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

CIPN

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

MABEL

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Nasopharyngeal Carcinoma Post IMRT

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

NeoTurbo

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial

Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China

Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

NPC-GTV

DIAMOND

NPC